In trial planning, which element must be clearly specified in a protocol before the trial begins?

Prepare for the ICH Good Clinical Practice (GCP) Exam for Certified Clinical Research Coordinator with engaging multiple-choice questions and detailed explanations. Elevate your understanding and expertise to excel in your certification exam!

Multiple Choice

In trial planning, which element must be clearly specified in a protocol before the trial begins?

Explanation:
Before a trial starts, the protocol must clearly specify all-important details of the trial design, how the trial will be conducted, and the principal features of the proposed statistical analysis. This comprehensive plan ensures everyone involved—investigators, sponsors, ethics committees, and regulators—has a precise, agreed-upon blueprint covering population, interventions, endpoints, timing, data collection methods, safety monitoring, and the approach to analyzing the data. When these elements are defined up front, it supports ethical review, data integrity, participant safety, and regulatory compliance, and it reduces the risk of ad hoc changes later that could bias results. Limiting the protocol to only design details or only statistical methods leaves out critical components like eligibility criteria, endpoints, monitoring plans, or data management, and focusing solely on randomization and sample size omits how the trial will be conducted and analyzed overall.

Before a trial starts, the protocol must clearly specify all-important details of the trial design, how the trial will be conducted, and the principal features of the proposed statistical analysis. This comprehensive plan ensures everyone involved—investigators, sponsors, ethics committees, and regulators—has a precise, agreed-upon blueprint covering population, interventions, endpoints, timing, data collection methods, safety monitoring, and the approach to analyzing the data. When these elements are defined up front, it supports ethical review, data integrity, participant safety, and regulatory compliance, and it reduces the risk of ad hoc changes later that could bias results. Limiting the protocol to only design details or only statistical methods leaves out critical components like eligibility criteria, endpoints, monitoring plans, or data management, and focusing solely on randomization and sample size omits how the trial will be conducted and analyzed overall.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy